New research in epigenetics reveals how early-life experiences influence gene expression and brain development.

Making smart grid technologies more user-friendly keeps the its usage increasing. A recent report from MarketsandMarkets said ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Sangamo Therapeutics, Inc. has groundbreaking treatments for neuropathic pain and Hemophilia A. Click for my updated look at ...

The Cambridge biotech, the first gene editing company to go public eight years ago, is laying off 180 workers as it focuses strictly on in-vivo, or inside the patient, gene editing. Big changes ...

Heading into 2025, there are multiple fronts where innovative tech marvels will lead the next evolution of global living as ...

It has also built its own manufacturing site and launched partnerships with six big pharma ... enough data to be sure that it’s safe. “Maybe in 50 years’ time we’ll be using gene editing ...

The EMA's human medicines advisory committee has recommended that BioMarin Pharmaceutical's haemophilia A gene therapy Roctavian ... armed with new data from a phase 3 trial, but set back its ...

“In our view, this is a big win for the stock in the backdrop ... In July, uniQure unveiled encouraging Phase I/II data for AMT-130, demonstrating that at 24 months, the higher dose of the gene ...

It’s a gene therapy designed to enter brain cells and block the genetic ... approval” — a type of clearance which allows drugs with limited supporting data to enter the market while their developers ...

As we begin 2025, we look back on all of the Huntington’s disease research news and progress the field has made in the last ...

A new study conducted at the Scojen Institute for Synthetic Biology at Reichman University's Dina Recanati School of Medicine ...